Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
ATP-Bench: Towards Agentic Tool Planning for MLLM Interleaved Generation
arXiv:2603.29902v1 Announce Type: new Abstract: Interleaved text-and-image generation represents a significant frontier for Multimodal Large Language Models (MLLMs), offering a more intuitive way to convey complex information. Current paradigms rely on either image generation or retrieval augmentation, yet they typically treat the two as mutually exclusive paths, failing to unify factuality with creativity. We argue that the next milestone in this field is Agentic Tool Planning, where the model
-
cs.AI, q-bio.NC updates on arXiv.org
-
MultiGen: Level-Design for Editable Multiplayer Worlds in Diffusion Game Engines
arXiv:2603.06679v2 Announce Type: replace Abstract: Video world models have shown immense promise for interactive simulation and entertainment, but current systems still struggle with two important aspects of interactivity: user control over the environment for reproducible, editable experiences, and shared inference where players hold influence over a common world. To address these limitations, we introduce an explicit external memory into the system, a persistent state operating independent o
MultiGen: Level-Design for Editable Multiplayer Worlds in Diffusion Game Engines
-
cs.AI, q-bio.NC updates on arXiv.org
-
QuestA: Expanding Reasoning Capacity in LLMs via Question Augmentation
arXiv:2507.13266v4 Announce Type: replace-cross Abstract: Reinforcement learning (RL) has emerged as a central paradigm for training large language models (LLMs) in reasoning tasks. Yet recent studies question RL's ability to incentivize reasoning capacity beyond the base model. This raises a key challenge: how can RL be adapted to solve harder reasoning problems more effectively? To address this challenge, we propose a simple yet effective strategy via Question Augmentation: introduce partial
QuestA: Expanding Reasoning Capacity in LLMs via Question Augmentation
-
Omics in Gastric
-
Targeting sialic acid metabolism: a therapeutic strategy against gastric cancer driven by WZ35
Cell Oncol (Dordr). 2026 Mar 23;49(2):60. doi: 10.1007/s13402-026-01194-6.ABSTRACTGlycolytic reprogramming is closely associated with the occurrence and progression of gastric cancer. Specifically, the energy derived from glucose metabolism and the cellular proteins by its intermediate products influence gastric cancer development. However, as an important branch of glucose metabolism, sialic acid metabolism and its mediated sialylation modifications remain insufficiently studied in gastric canc
Targeting sialic acid metabolism: a therapeutic strategy against gastric cancer driven by WZ35
Cell Oncol (Dordr). 2026 Mar 23;49(2):60. doi: 10.1007/s13402-026-01194-6.
ABSTRACT
Glycolytic reprogramming is closely associated with the occurrence and progression of gastric cancer. Specifically, the energy derived from glucose metabolism and the cellular proteins by its intermediate products influence gastric cancer development. However, as an important branch of glucose metabolism, sialic acid metabolism and its mediated sialylation modifications remain insufficiently studied in gastric cancer, and their specific relationship with malignant tumor progression requires further exploration. This study employed a multi‑omics approach, integrating metabolomics, single‑cell RNA sequencing, and bulk RNA sequencing analyses, to investigate the metabolic landscape of gastric cancer and its associated alterations. The results indicated that sialic acid is a characteristic metabolite in malignant gastric cancer tissues. It modulates biological functions such as immune response, proliferative activity, and metabolic remodeling within gastric cancer tissues by influencing sialylation modifications. Furthermore, we identified the drug WZ35, which can inhibit the malignant proliferation of gastric cancer by targeting both sialic acid metabolism and sialylated protein modifications. We put forward a conjecture that the metabolism and modification of sialic acid promote the malignant development of gastric cancer, and we discovered that the drug WZ35 has an inhibitory effect on the sialic acid metabolism of gastric cancer.
GRAPHICAL ABSTRACT:
PMID:41870836 | PMC:PMC13009457 | DOI:10.1007/s13402-026-01194-6